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T reatment for advanced aggressive non-Hodgkin’s lymphoma (NHL) —the most common type of 
which is diffuse large B-cell lymphoma (DLBCL) —has 
progressed rapidly since the 1970s.  CHOP therapy 
(cyclophosphamide,  doxorubicin,  vincristine,  and 
prednisone) was developed in 1976 as a first-generation 
cancer regimen requiring the once-monthly adminis-
tration of a combination of the several different types of 
chemotherapeutic agents.  Based on the hypothesis the 
intensification of treatment would lead to improved 
outcomes,  second-generation cancer regimens were 
developed by combining 6 or more drugs with different 
mechanisms of action over a short period.  Since the late 
1980s,  third-generation regimens have been developed 
by adding drugs with relatively less bone-marrow sup-
pression activity to be administered between intensive 
chemotherapy courses,  with the aim of reducing the 
treatment intervals.
The results of a large-scale randomized controlled 
trial of untreated,  advanced-stage aggressive NHL (pre-
dominantly DLBCL) were reported in 1993.  The 3-year 
survival rate did not differ significantly between the 
patients who were treated with first-generation CHOP 
therapy and those treated with second-/third-genera-
tion combination chemotherapy,  but the CHOP ther-
apy was the least toxic.  CHOP therapy has thus been 
established as a standard therapy for aggressive NHL,  
including DLBCL [1].
A controlled trial for untreated,  limited-stage 
aggressive NHL compared 8 courses of CHOP therapy 
and three courses of CHOP therapy followed by 
involved field radiation therapy (IFRT),  and the 
patients who received three courses of CHOP therapy 
Acta Med.  Okayama,  2018
Vol.  72,  No.  3,  pp.  315-318
CopyrightⒸ 2018 by Okayama University Medical School.
http ://escholarship.lib.okayama-u.ac.jp/amo/Clinical Study Protocol
R-mini CHP in ≥ 80-year-old Patients with Diffuse Large B-cell Lymphoma:  
A Multicenter,  Open-label,  Single-arm Phase II Trial Protocol
Yasuhiko Miyataa＊,  Akiko M.  Saitob,  Takahiro Yanoc,  Isao Yoshidad,   
Youko Suehiroe,  Naoki Haradaf,  and Hirokazu Nagaia
aDepartment of Hematology,  bClinical Research Center,  Nagoya Medical Center,  Nagoya 460-0001,  Japan,   
cDepartment of Hematology,  Tokyo Medical Center,  Tokyo 152-8902,  Japan,   
dDepartment of Hemato-oncology,  Shikoku Cancer Center,  Ehime 791-0280,  Japan,   
eDepartment of Hematology,  Kyushu Cancer Center,  Fukuoka 811-1395,  Japan,   
fDepartment of Hematology,  Kyushu Medical Center,  Fukuoka 810-8563,  Japan
In very-elderly diffuse large B-cell lymphoma (DLBCL) patients,  treatment intensities must be lowered due to 
the risks of comorbidities and organ function deterioration,  and treatment outcomes are worse compared to 
younger patients.  Very-elderly patients are often excluded from DLBCL clinical trials,  and optimal treatments 
and dosages are not established.  In this clinical trial,  we examined the efficacy and safety of 6 courses of R-mini 
CHP therapy (cf.,  CHOP [cyclophosphamide,  doxorubicin,  vincristine,  and prednisone]) in which vincristine 
is omitted to avoid the peripheral neuropathy that reduces elderly patients’ quality of life,  as remission induc-
tion therapy in DLBCL patients aged ≥ 80 years.
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followed by IFRT achieved significantly better 5-year 
progression-free survival (PFS) and overall survival 
(OS) rates [2].  However,  in the follow-up surveillance,  
recurrence after 5 years was more frequent in the three 
CHOP courses/IFRT group,  and the PFS after 7 years 
and OS after 9 years were found to be better in 8 courses 
of CHOP group.
The CD20 antigen is a differentiation antigen 
expressed in nearly all mature B lymphocytes (plasma 
cells are an exception),  and it plays an important role in 
B-cell activation.  CD20 expression is also observed in 
around 95% of mature B-cell lymphomas and essen-
tially all cases of DLBCL.  Rituximab is a chimeric 
monoclonal antibody targeted against the CD20 antigen 
and a chimeric anti-CD20 antibody with a recognition 
site (variable region) originating from mouse and a 
remainder (constant region) originating from human.  
The CD20 antigen has excellent properties as a target for 
antibody therapy because it does not exhibit the shed-
ding and internalization associated with antibody bind-
ing.  Rituximab monotherapy was first used in the treat-
ment of B-cell follicular lymphoma (FL),  and it has 
shown significant clinical activity.  It thus became evi-
dent that rituximab would improve outcomes by being 
administered concomitantly with chemotherapy,  and 
this combination is now considered a standard therapy 
for FL.
DLBCL is also a mature B-cell lymphoma and is 
CD20-positive; therefore,  the combined use of ritux-
imab with chemotherapy has been hypothesized to be an 
effective treatment for DLBCL.  In fact,  CHOP therapy 
combined with rituximab (R-CHOP therapy) signifi-
cantly improved the complete response rate,  PFS rate,  
and OS compared to CHOP therapy alone in untreated 
patients with DLBCL aged 60-80 years [3]. In addition,  
R-CHOP therapy was demonstrated to be beneficial in 
young low-risk DLBCL patients [4],  and it has been 
established as a standard therapy for low-risk DLBCL in 
patients up to the age of 80 years.
Many clinical trials have been conducted with the 
aim of improving outcomes in elderly patients with 
DLBCL,  and it was shown that adding rituximab to 
chemotherapy and maintaining the treatment intensity 
improves the outcomes [3 , 5]; however,  the patients 
enrolled in those trials were aged 61-80 years.
Very elderly patients (aged ≥ 80 years) often have 
comorbidities and/or a loss of major organ reserve such 
as that of the heart,  liver,  kidneys,  and bone marrow,  
and these patients experience poorer outcomes [6 , 7].  
In the cases of very elderly patients,  it is difficult to 
adapt high-intensity treatments similar to those used for 
patients below the age of 80,  and the dosages of anti-
cancer drugs are frequently reduced by physicians’ 
choices.  Consequently,  therapy with an unnecessari-
ly-lowered intensity may be administered [8 , 9],  or 
chemotherapy may be even considered contraindicated 
based on age alone [10 , 11].  These are thought to be one 
of the causes of poorer outcomes in the elderly patients.
In addition,  very elderly patients are much more 
likely to experience more intense treatment-related tox-
icities,  and thus they are also more likely to experience 
a decline in quality of life (QOL).  Thus,  very elderly 
patients are often excluded from clinical trials,  and 
optimal treatments and dosages for these patients are 
not established.  Only a limited amount of information 
is available about these cases; this is a single report by 
Peyrade in which the 2-year PFS rate was 47%,  the 
2-year OS rate was 59%,  and the overall response rate 
was 73% [5].
As the populations of most industrialized countries 
have continued to age,  there has been a significant 
increase in the number of elderly patients,  including 
very elderly patients,  with DLBCL.  Thus,  the purpose 
of the present clinical trial is to establish candidate 
treatments that are effective and minimize any decline 
in QOL for very elderly patients with DLBCL (aged ≥ 80 
years).  This is also regarded as important for the estab-
lishment of treatment strategies for elderly patients with 
other types of malignant lymphoma in Japan.
Endpoints
Primary endpoint. The primary endpoint of this 
trial is the 2-year progression-free survival (PFS) rate.
Secondary endpoints. The secondary endpoints 
are (1) the 2-year overall survival (OS) rate,  (2) the 
complete remission rate,  (3) the safety profile of the 
mini-CHP regimen,  i.e.,  the incidences of adverse 
events,  and (4) the incidence of febrile neutropenia.
Eligibility Criteria
Inclusion criteria. The inclusion criteria for the 
trial are as follows.  (1) Pathological diagnosis: diffuse 
large B-cell lymphoma,  NOS (not otherwise speci-
fied); (2) CD20 antigen-positive; (3) CS (clinical stage) 
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I bulky,  CSII/III/IV; (4) presence of measurable 
lesions; (5) no prior therapy for lymphoma except 
pre-treatment with prednisolone; (6) age ≥ 80 years 
old; (7) Performance Status (PS) (ECOG [Eastern 
Cooperative Oncology Group]) 0-2; (8) adequate organ 
functions; (9) informed consent is provided by the 
patient.
Exclusion criteria. The exclusion criteria for the 
trial are as follows.  (1) The presence of active infection,  
(2) the presence of central nervous invasion,  (3) a past 
history of glaucoma,  (4) a past history of severe drug 
allergy,  (5) HIV Ab-positive or HTLV-1 Ab-positive,  
(6) HBsAg-positive or HCV Ab-positive,  (7) severe 
cardiac disease,  (8) hepatic cirrhosis,  (9) uncontrolla-
ble diabetes mellitus,  (10) being on dialysis,  (11) lung 
fibrosis or interstitial pneumonitis,  (12) other active 
malignancies,  (13) pregnant or breastfeeding female,  
(14) severe mental disorder,  (15) continuous systemic 
administration of a steroid,  and (16) judged inappro-
priate for other reasons.
Methods
Study design. This is a multicenter,  open-label,  
single-arm phase II clinical trial involving 24 institutions.  
The trial was approved by Japan’s National Hospital 
Organization Central Research Ethics Committee 
(H24-NHO (hematology)-01).  Registration of the trial 
participants began in May 2013 and was completed in 
October 2016.  The observation period is ongoing.  The 
study was registered in the UMIN-CTR (University 
Hospital Medical Information Network Clinical Trials 
Registry) on July 19,  2013 (UMIN 000011234).
The trial’s design is shown in Fig. 1.
Treatment methods. For elderly patients,  the 
intensification of treatment will cause severe adverse 
effects,  reducing their QOL.  We will thus examine 
whether six courses of R-mini CHP therapy as remis-
sion induction therapy is effective and minimizes any 
decline in QOL in very elderly DLBCL patients (i.e.,  
those aged 80 years or older).  R-mini CHP therapy is a 
modification of the R-mini CHOP therapy which has 
successfully reduced febrile neutropenia as a backbone 
regimen,  and but R-mini CHP therapy omits vincris-
tine in comparison with R-mini CHOP therapy.  R-mini 
CHP therapy can reduce the incidence of severe infec-
tions such as febrile neutropenia to the same extent as 
R-mini CHOP therapy.  Moreover,  R-mini CHP therapy 
can avoid peripheral neuropathy by omitting vincris-
tine.  Consequently,  R-mini CHP therapy is expected to 
contribute to the maintenance of QOL in this patient 
population.
One course of R-mini CHP therapy consists of ritux-
imab (375 mg/m2 of body surface area/day) adminis-
tered on day 1,  doxorubicin hydrochloride (25 mg/m2 
of body surface area/day) and cyclophosphamide 
(500 mg/m2 of body surface area/day) administered on 
any one day of day 1 to day 3,  and prednisolone 
(40 mg/m2 of body surface area/day) administered from 
one of day 1-day 3 for 5 days.  For cases in which pro-
gression disease (PD) is confirmed as an intermediate 
therapeutic effect after three courses of R-mini CHP 
therapy,  the protocol treatment will be discontinued.
Although no particular stipulations will be made in 
terms of subsequent treatment if bulky lesions are pres-
ent before treatment,  involved field radiation (IFRT) 
will be recommended,  with consideration given to the 
patient’s condition.  Up to two courses of an additional 
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Fig. 1　 Trial design.
administration of rituximab within 6 months of the 
completion of six courses of R-mini CHP therapy will 
also be allowed.
Statistical Considerations
Sample size. Patients are followed up for 2 years 
after the last patient has been included.  The primary 
endpoint is the 2-year PFS rate.  We assume the expected 
and threshold values for the primary endpoint of 54% 
and 40%,  respectively.  Forty patients are required with 
an α error of 0.10 (two-sided) and a β error of 0.80.
Statistical analysis. The primary analysis will 
verify whether R-mini CHP therapy for patients with 
DLBCL aged ≥ 80 years is sufficiently effective and 
whether it has an acceptable range of adverse events 
(treatment-related toxicity and treatment-related mor-
tality).  The 2-year PFS rate,  which is the primary end-
point,  is to be estimated using the Kaplan-Meier method,  
with the 95% confidence interval calculated using 
Greenwood’s formula.  All patients will be analyzed,  
with the exceptions of patients who subsequently become 
ineligible cases of duplicate registration or mis-registra-
tion,  and patients excluded from the analysis as a result 
of investigations by the Protocol Review Committee/
Monitoring Review Committee.
Interim analysis and monitoring. An interim 
analysis will not be conducted.  Monitoring will be per-
formed twice annually,  in principle,  in order to assess 
whether the study is proceeding safely and in accor-
dance with protocol,  and whether data are being col-
lected correctly.
Discussion
The purposes of this clinical trial are to establish 
candidate treatments that are effective and to minimize 
any decline in QOL for DLBCL patients aged ≥ 80 years.  
This is also regarded as important for the establishment 
of treatment strategies for elderly patients with other 
types of malignant lymphoma in Japan.
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